Nuvation Bio financials
$5.62+0.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $62.9M | $7.9M | $0.00 | $0.00 | — |
| Gross profit | $54.5M | $795.0K | $0.00 | $0.00 | — |
| Gross margin | 86.6% | 10.1% | — | — | — |
| Operating income | -$213.1M | -$592.6M | -$99.8M | -$119.7M | -$93.3M |
| Net income | -$204.6M | -$567.9M | -$75.8M | -$104.2M | -$86.8M |
| Net margin | −325.3% | −7213.8% | — | — | — |
| Diluted EPS | $-0.60 | $-2.11 | $-0.35 | $-0.48 | $-0.44 |
| EBITDA | -$211.3M | -$591.9M | -$99.6M | -$119.5M | -$93.1M |
| Operating cash flow | -$173.4M | -$130.4M | -$68.0M | -$96.1M | -$68.2M |
| Free cash flow | -$181.8M | -$130.6M | -$68.1M | -$96.5M | -$68.5M |
| Diluted shares | 341.5M | 268.8M | 218.9M | 216.7M | 197.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $164.1M | $35.7M | $42.6M | $101.1M | $132.4M |
| Short-term investments | $365.1M | $467.0M | $568.6M | $559.9M | $636.0M |
| Total debt | $62.5M | $6.3M | $0.00 | $0.00 | $0.00 |
| Total assets | $594.8M | $540.6M | $621.5M | $672.1M | $776.2M |
| Total liabilities | $289.1M | $76.8M | $16.4M | $17.1M | $30.2M |
| Shareholders' equity | $305.7M | $463.8M | $605.1M | $655.1M | $746.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology